Tacrolimus Concentration Is Effectively Predicted Using Combined Clinical and Genetic Factors in the Perioperative Period of Kidney Transplantation and Associated with Acute Rejection

Fang Cheng, Qiang Li, Zheng Cui, Zhendi Wang, Fang Zeng, Yu ZhangJournal of Immunology Research 2022 · DOI

TL;DR

This study reveals that combining genetic information (specifically CYP3A5 genotype) with clinical factors like red blood cell count, albumin levels, and the use of Wuzhi capsule significantly improves the prediction of tacrolimus drug levels in kidney transplant patients during the critical perioperative period. Higher early tacrolimus concentrations were found to be associated with an increased risk of acute rejection, highlighting the importance of personalized dosing strategies.

What Problem Does This Paper Address?

Tacrolimus is a cornerstone immunosuppressant for kidney transplant recipients, but its effectiveness is hampered by highly variable drug levels (pharmacokinetics or PK) and a narrow therapeutic window, leading to a risk of toxicity or rejection. While genetic factors, particularly the CYP3A5 gene, are known to influence tacrolimus metabolism, they don't fully explain the observed variability. The perioperative period is especially challenging due to rapid physiological changes and the vulnerability of patients. This paper aims to identify key clinical and genetic factors that predict tacrolimus PK variability in the early post-transplant phase and to understand how these early drug levels relate to crucial clinical outcomes like delayed graft function (DGF) and acute rejection (AR).

Methods

The researchers conducted a retrospective analysis of 256 kidney transplant recipients. They collected data on patient demographics, clinical status, immunosuppressive regimens, and laboratory findings. Crucially, they performed genotyping for several genes known to influence drug metabolism and transport, including CYP3A4, CYP3A5, ABCB1, ABCC2, PXR, and POR. Tacrolimus concentrations in whole blood were measured regularly during the perioperative period.

To analyze the data, they employed a multivariable mixed-effects regression model to identify factors associated with the tacrolimus concentration/dose ratio (C/D), a measure of drug clearance. They built two predictive models: one based solely on CYP3A5 genotype and another incorporating both genetic and clinical factors. Statistical analysis was used to assess the association between early tacrolimus concentrations and the incidence of DGF and AR.

Datasets

The study utilized data from 256 kidney transplant recipients treated at Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, between January 2015 and December 2019. This dataset included clinical, laboratory, and genetic information. No new benchmark datasets were introduced.

Key Insights and Ideas

  • Genetics isn't the whole story: While CYP3A5 genotype is a significant predictor of tacrolimus levels, it only explains a portion of the variability. This underscores the need to consider other factors.
  • Clinical factors matter significantly: Red blood cell count (RBC), albumin (ALB) levels, and the use of the traditional Chinese medicine Wuzhi capsule (WZC) were identified as important clinical predictors of tacrolimus concentration. This suggests that readily available clinical data can contribute substantially to personalized dosing.
  • Perioperative period is critical: The study emphasizes the unique challenges and variability of tacrolimus PK during the immediate post-transplant phase, a period where patients are most vulnerable.
  • Early concentration predicts rejection: Higher tacrolimus concentrations in the early perioperative period were associated with an increased risk of acute rejection, but not delayed graft function. This finding is crucial for guiding early dosing strategies to prevent rejection.
  • Combined model is superior: A model that integrates both genetic and clinical factors provides a much more comprehensive prediction of tacrolimus PK variability than genetic factors alone.

Key Results

  • The CYP3A5 genotype was strongly associated with tacrolimus concentration/dose ratio (C/D).
  • ABCB1 (rs1045642 and rs2032582) and ABCC2 (rs3740066) genotypes also showed potential independent effects on early tacrolimus C/D.
  • Red blood cell count (RBC) and albumin (ALB) levels were the most significant clinical factors associated with tacrolimus C/D, with RBC showing a substantial impact.
  • Wuzhi capsule (WZC) use was also found to influence tacrolimus PK.
  • A model combining pharmacogenetic and clinical factors explained 43.4% of tacrolimus PK variability, a significant improvement over the 16.3% explained by CYP3A5 genotype alone.
  • Increasing early tacrolimus concentrations were associated with a higher incidence of acute rejection (AR).
  • Delayed graft function (DGF) was not significantly associated with early tacrolimus concentrations.

Limitations and Future Work

The authors acknowledge several limitations:

  • Single-center retrospective design: This limits the generalizability of the findings, and multicenter studies are needed for validation.
  • Intermittent tacrolimus monitoring: Tacrolimus concentrations were not measured daily, potentially leading to missed fluctuations, especially on weekends.
  • Focus on early period: The study primarily focused on the early perioperative period, and the long-term relationship between tacrolimus concentration and outcomes was not fully explored.
  • Limited scope of clinical outcomes: The study did not investigate other potential toxicities like de novo diabetes or tremor, nor did it consider surgical or donor-specific factors (e.g., DSA, HLA, PRA).

Future work could involve prospective, multicenter studies to validate these findings and develop more robust, individualized dosing algorithms that integrate TDM with clinical and pharmacogenetic information for optimal patient management. Further investigation into the impact of other clinical factors and long-term outcomes is also warranted.

Summary updated

Abstract

Combined analysis of genotype and specific clinical factors is important for the formulation of precise tacrolimus dose regimens in the early stage after kidney transplantation.
BibTeX
@article{cheng2022tacrolimus,
  author = {Fang Cheng and Qiang Li and Zheng Cui and Zhendi Wang and Fang Zeng and Yu Zhang},
  title = {{Tacrolimus Concentration Is Effectively Predicted Using Combined Clinical and Genetic Factors in the Perioperative Period of Kidney Transplantation and Associated with Acute Rejection}},
  journal = {Journal of Immunology Research},
  year = {2022},
  doi = {10.1155/2022/3129389},
}
Figure